Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.1.8 (cholinesterase)
 12,691 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The observation of neurotoxicity in a subject with long-term exposure to high levels of carbaryl has prompted the review of the potential for carbaryl to cause toxicity. Short-term studies in animal species and humans confirm that carbaryl can cause toxicity due to cholinesterase inhibition. Wide variations in the dosage required to induce toxicity in either different species or in one species by different routes of administration can in part be explained by differences in drug disposition. However, the information available about carbaryl's disposition in humans is inadequate to interpret the relevance of animal studies to humans. Limited long-term exposure studies in rats and dogs have not demonstrated unexpected adverse effects. However, long-term exposure in pigs results in a progressive neuromyopathy that is associated with structural damage and is not acutely reversible with atropine. Published information on the effects of long-term exposure to carbaryl in humans is limited and has not identified any adverse effects. It is concluded that not enough information is available to exclude the possibility that sustained high levels of exposure to carbaryl could be associated with neurotoxic or myotoxic responses in humans.
 ...
PMID:Is carbaryl as safe as its reputation? Does it have a potential for causing chronic neurotoxicity in humans? 308 75

Myasthenia gravis is characterized by variable ocular and skeletal muscle weakness. Peak incidence is in young women and older men. Thymomas are present in 30 percent of myasthenic patients over age 40. Binding of acetylcholine receptors by IgG antibodies may be the mechanism of the neuromuscular disorder. Repetitive nerve stimulation (Jolly test), provocative tests with quinine or curare and the edrophonium test (cholinesterase inhibition) are the diagnostic maneuvers employed.
 ...
PMID:The neuromuscular junction. Part II: myasthenia gravis. 745 20

Neuromuscular disorders can impose significant disability in patients by virtue of weakness, pain, and sensory and autonomic symptoms and deficits. For all of these disorders, supportive measures, appropriate physical therapy, and respiratory support are beneficial. Pain management can be accomplished by the use of antiepileptic medications, such as carbamazepine, phenytoin, valproic, and gabapentin. Tricyclic antidepressants can also be helpful for pain management and depression. Benzodiazepines and baclofen are helpful for management of spasticity. No specific treatment exists yet for the motor neuron disorders. In peripheral neuropathies, identifying and treating the cause is most important. In other neuropathies, such as in acute or chronic inflammatory demyelinating neuropathies, immunosuppression is indicated. Myasthenia gravis can be treated with cholinesterase inhibitors and immunosuppression. A specific treatment does not exist yet for muscular dystrophies. Immunosuppression is helpful in patients with inflammatory myopathies. Toxic myopathies can be treated by removing the causative agent and by supportive measures. Endocrine myopathies will respond to treatment of the primary endocrinopathy.
 ...
PMID:Diagnostic algorithms for neuromuscular diseases. 992 72